Literature DB >> 31633383

Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on 'preclinical and early-phase clinical pharmacology'.

Alessandro Leonetti1, Lenka Boyd2,3, Jacopo Giuliani4, Elisa Giovannetti2,5, Ingrid Garajová1.   

Abstract

Introduction: In the era of 'precision' oncology, novel clinical trial designs have emerged, in order to better address the final goal of translating the above-mentioned preclinical discoveries into the clinic. Nonetheless, in aiming to achieve the greatest clinical benefit to patients, some limitations of these novel approaches from the statistical, methodological and practical point of view need to be overcome.Areas covered: In the present review, a short overview of basket trials, umbrella trials and platform trials are discussed, in particular advantages and disadvantages of such experimental approaches.Expert opinion: Master protocols represent the future of clinical oncology research. The possibility of investigating multiple biomarkers and therapeutic regimens under one study is a strong advantage over traditional trials, and it can lead to quick implementation of new, promising treatments or biomarkers into the clinic.

Entities:  

Keywords:  Clinical trial; basket trial; precision oncology; umbrella trial

Mesh:

Year:  2019        PMID: 31633383     DOI: 10.1080/17512433.2019.1683446

Source DB:  PubMed          Journal:  Expert Rev Clin Pharmacol        ISSN: 1751-2433            Impact factor:   5.045


  2 in total

Review 1.  Study designs for clinical trials applied to personalised medicine: a scoping review.

Authors:  Cecilia Superchi; Florie Brion Bouvier; Chiara Gerardi; Montserrat Carmona; Lorena San Miguel; Luis María Sánchez-Gómez; Iñaki Imaz-Iglesia; Paula Garcia; Jacques Demotes; Rita Banzi; Raphaël Porcher
Journal:  BMJ Open       Date:  2022-05-06       Impact factor: 3.006

2.  Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours.

Authors:  P Garrido; R Hladun; E de Álava; R Álvarez; F Bautista; F López-Ríos; R Colomer; F Rojo
Journal:  Clin Transl Oncol       Date:  2021-02-23       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.